Vibostolimab is a human IgG1 aTIGIT mAb that was first tested in humans in a phase I trial (NCT02964013) with a pan-tumor arm A and an arm B that included patients with mNSCLC who were treatment-naïve or had been pretreated with one or more lines of treatment, including anti PD-(L)1 immunotherapy [113]. This evidence concerns the gene CD274 and neoplasm.